OncLive® On Air podcast

Artwork

Fitness Audioboom OncLive® On Air Oncology Science Medicine Exclusive Interviews

Player FM - Internet Radio Done Right

29 subscribers

Adăugat seven ani în urmă

Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

<

<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/peak-travel">Peak Travel</a></span>

<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/peak-travel">Peak Travel</a></span> podcast artwork

<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/peak-travel">Peak Travel</a></span> podcast artwork

1
Peak Travel

acum 7 zileacum 7d ago

Lunar+

Travel can do amazing things: broaden horizons, build relationships, and rejuvenate the soul. But often, those experiences come at a cost. This is Peak Travel, a new podcast from WHYY about how travel shapes communities in hot-spots around the world. We’ll share the wonder that comes with exploring new places, as well as the harm that our worst travel habits can cause. And we’ll try to figure out how we can do it better. Each episode transports you to a new destination. You’ll meet the people who call that place home, hear their stories, and come to understand how tourism has changed their everyday lives. Supported by rich, on-location sound from around the world, Peak Travel unpacks the $1.9 trillion travel industry and its impact on people and the planet.

OncLive® On Air

Distribuie

Pagina seriei•Feed

Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

… continue reading

600 episoade

#Fitness #Audioboom #OncLive® On Air #Oncology #Science #Medicine #Exclusive Interviews

Artwork

OncLive® On Air

29 subscribers

updated acum 4 zile

Distribuie

Pagina seriei•Feed

Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

… continue reading

600 episoade

#Fitness #Audioboom #OncLive® On Air #Oncology #Science #Medicine #Exclusive Interviews

모든 에피소드

×

1
S12 Ep33: Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD 18:19

acum 4 zile18:19

Redare mai Târziu

Redare mai Târziu

18:19

In today’s episode, supported by EMD Serono, we had the pleasure of speaking with Chandler Park, MD, about the first-line treatment of patients with bladder cancer. Dr Park is a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky. In our exclusive interview, Dr Park discussed the core regimens in the current frontline bladder cancer treatment paradigm, ways that this paradigm is expected to evolve in the coming months and years, and how the choice of frontline therapy influences treatment decision-making regarding subsequent lines of therapy.…

1
S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD 10:30

acum 5 zile10:30

Redare mai Târziu

Redare mai Târziu

10:30

In this week's episode of MedNews Week 's Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, as well as a genitourinary medical oncologist at the UCSF Helen Diller Comprehensive Cancer Center. Drs Park and Koshkin discussed recent developments in bladder cancer management, including the significant benefits of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) compared with platinum-based chemotherapy in the metastatic setting, key outcomes from the phase 3 NIAGARA trial (NCT03732677) of perioperative durvalumab (Imfinzi) plus chemotherapy in muscle-invasive bladder cancer, the potential for disitamab vedotin (RC48-ADC) to join the advanced urothelial cancer treatment paradigm, and what the future may look like for HER2-targeted therapies in this disease.…

1
S12 Ep31: Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory… 13:54

acum 7 zile13:54

Redare mai Târziu

Redare mai Târziu

13:54

In today’s episode, we invited experts from across oncology specialties to discuss the long-term effects of the COVID-19 pandemic—the onset of which occurred 5 years ago. Our guests shared how the pandemic's lingering effects continue to shape patient care. We heard from: Ramez N. Eskander, MD, a gynecologic oncologist and assistant professor of obstetrics, gynecology, and reproductive sciences at the University of California San Diego Health Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York Benjamin Herzberg, MD, an assistant professor of medicine at Columbia University Medical Center and an oncologist at Herbert Irving Comprehensive Cancer Center in New York, New York Kelly McCann, MD, PhD, an assistant professor and breast medical oncologist at UCLA Health’s David Geffen School of Medicine in Los Angeles, California Gregory Roloff, MD, a hematologist/oncologist at the University of Chicago Medicine in Illinois…

1
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD 15:16

acum 11 zile15:16

Redare mai Târziu

Redare mai Târziu

15:16

In today’s episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut. In this exclusive interview, Dr Braun discussed the rationale for investigating molecular factors that contribute to exceptional ICI responses among patients with RCC, as well as the key findings from this study. He also shared how these findings may affect cancer care and influence shared decision-making strategies for patients receiving immunotherapy.…

1
S12 Ep29: Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc 20:48

acum 12 zile20:48

Redare mai Târziu

Redare mai Târziu

20:48

In this week's episode of MedNews Week 's Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Ann S. LaCasce, MD, MMSc, an associate professor of medicine and a lymphoma specialist at Dana-Farber Cancer Institute in Boston, Massachusetts and Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology. LaCasce shares her journey into hematologic oncology, shaped by early mentors — including her father — and how a passion for art history sparked her interest in pattern recognition and morphology , which are skills central to lymphoma diagnosis. Their discussion explores key advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity by minimizing radiation in early-stage Hodgkin lymphoma. LaCasce also highlights the incorporation of novel agents, such as brentuximab vedotin (Adcetris) and checkpoint inhibitors, into frontline regimens aimed at improving outcomes without increasing treatment burden. Park and LaCasce also discuss the importance of education and mentorship. She describes her work directing one of the country’s largest hematology/oncology fellowship programs and her leadership in founding the international Women in Lymphoma network to foster collaboration and gender equity in the field. From clinical innovation to workforce development, LaCasce provides a comprehensive look into the role of multidisciplinary research, mentorship, and global engagement in advancing the future of lymphoma management.…

1
S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD 11:22

acum 14 zile11:22

Redare mai Târziu

Redare mai Târziu

11:22

In today’s episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston. The phase 3 HARMONi-2 trial (NCT05499390) investigated ivonescimab vs pembrolizumab (Keytruda) in patients with locally advanced or metastatic, PD-L1–positive NSCLC without sensitizing EGFR mutations or ALK translocations. At the preplanned interim analysis, at a median follow-up of 8.7 months (IQR, 7.1-10.3), the median progression-free survival was significantly longer in the ivonescimab arm (n = 198) vs the pembrolizumab arm (n = 200), at 11.1 months (95% CI, 7.3-not estimable) vs 5.8 months (95% CI, 5.0-8.2), respectively (stratified HR, 0.51; 95% CI, 0.38-0.69; 1-sided P < .0001). The objective response rates were 50% (95% CI, 43%-57%) and 39% (95% CI, 32%-46%) in these respective arms. In our exclusive interview, Dr Le discussed the rationale for the HARMONi-2 trial, key findings from the study, and where these findings position the potential role of ivonescimab in the PD-L1–positive NSCLC treatment paradigm.…

1
S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD 9:57

acum 18 zile9:57

Redare mai Târziu

Redare mai Târziu

9:57

In today’s episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.…

1
S12 Ep27: Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD 19:58

acum 21 zile19:58

Redare mai Târziu

Redare mai Târziu

19:58

Dr Emadi discussed how the combination of venetoclax (Venclexta) plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia, including in those with prior exposure to venetoclax. He detailed data on the combination from a phase 1 study published in Blood , the significance of the findings, and more.…

1
S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD 9:30

acum 25 zile9:30

Redare mai Târziu

Redare mai Târziu

9:30

In our exclusive interview, Dr Uboha discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 RATIONALE-306 trial (NCT03783442), and considerations for integrating this agent into the ESCC treatment paradigm.

1
S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD 23:04

acum 26 zile23:04

Redare mai Târziu

Redare mai Târziu

23:04

In this episode of MedNews Week 's Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program at Fred Hutchinson Cancer Center and a professor of medicine at the University of Washington School of Medicine, about key updates from the 2025 Genitourinary Cancers Symposium and the evolving treatment paradigm for muscle-invasive bladder cancer (MIBC).…

1
S12 Ep24: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes 54:09

acum 27 zile54:09

Redare mai Târziu

Redare mai Târziu

54:09

This featured podcast includes a discussion with 3 experts on best practices in the care of patients with chronic lymphocytic leukemia (CLL), the most common hematologic leukemia diagnosed among adults worldwide. Treatment for CLL continues to evolve rapidly. Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes is designed to share new clinically relevant data with appropriate context so clinicians can better care for patients with CLL.…

1
S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc 5:27

acum 28 zile5:27

Redare mai Târziu

Redare mai Târziu

5:27

Dr Kaklamani discusses the mechanism of action of inavolisib, the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm, and considerations for early biomarker testing in patients with breast cancer.

1
S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD 7:48

acum 5 weeks7:48

Redare mai Târziu

Redare mai Târziu

7:48

Dr Tap discusses the significance of the FDA approval of vimseltinib for symptomatic TGCT, in which surgical resection may worsen functional limitation or cause severe morbidity. He also discussed key efficacy and safety data from the pivotal phase 3 MOTION trial and the increasingly important role that multidisciplinary collaboration will play as this targeted therapy is further integrated into clinical practice.…

1
S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma 30:09

acum 5 weeks30:09

Redare mai Târziu

Redare mai Târziu

30:09

This featured podcast brings together 2 experts to discuss the care of patients with epithelioid sarcoma.

1
S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD 7:39

acum 5 weeks7:39

Redare mai Târziu

Redare mai Târziu

7:39

Dr Fakih discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial (NCT05198934), and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

Ascultă peste 500 de subiecte

Ghid rapid de referință

Podcast-uri de top

Florin Rosoga Podcast

Morning Glory cu Răzvan Exarhu

Epic Show Podcast

UPGRADE 100 Podcasts

România în direct - Europa FM

Deşteptarea - Europa FM

Ajutor/FAQ | Upgrade | Advertise

Arte|Afaceri|Comedie|Economie|Divertisment|Știri|Politică|Religie

Ştiinţă|Fotbal|Sport|Povestiri|Tehnologie|True Crime

Drepturi de autor 2025 | Harta site-ului | Politica de confidenţialitate | Termenii serviciului | | Copyright

Listen to this show while you explore